Half Year 2023 Renalytix PLC Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Unidentified Participant - BTIG - Analyst : Hey guys, this is [Vivian] on for Mark. Thanks for taking the question. So do you have any outlook for visibility if the 950 ICR rate can continue over the course of 2023, I think you also mentioned getting paid above 950 in some instances and talked about diversity and revenue going forward, so just any guidance you can share on ASP? Thanks. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 30, 2023 / 12:30PM, RENX.L - Half Year 2023 Renalytix PLC Earnings Call

Question: Unidentified Participant - BTIG - Analyst : Okay, perfect, thank you. And then could you just provide an update on the number of private payers that you're in contract with and if you could potentially share the number of covered lives as well? And then just a follow up to that, I think you've also talked about peer review or real world evidence moving the needle for payers. So can you just update us on any timing we should expect there on real world evidence publication? Thanks.

Question: Unidentified Participant - BTIG - Analyst : Awesome, thanks for taking the questions.

Question: Chaitanya Gollakota - H.C. Wainwright - Analyst : Hi. This is Chaith on behalf of Yi Chen. Thank you. I mean, most of my questions have been answered. So I'll just -- the one quick question on the FDA review process, what's the nature of questions or concerns that the FDA is posing to you? Thank you again.

Question: Chaitanya Gollakota - H.C. Wainwright - Analyst : Yes. Thank you.